Featuring slide presentations and related discussion from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang. Published November 29, 2021. (Faculty Presentations)
TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Courtney D DiNardo, MD, MSCE
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Advisory Committee: Foghorn Therapeutics, Gilead Sciences Inc, Immune-Onc Therapeutics Inc, Novartis, Takeda Oncology; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astex Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, CleaveTherapeutics, Daiichi Sankyo Inc, Immune-Onc Therapeutics Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Scientific Advisory Board with Stock Options: Notable Labs.
Daniel A Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Robert H Allen, MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado
Advisory Committee: AbbVie Inc, Amgen Inc, Aprea Therapeutics, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Foghorn Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlycoMimetics Inc, Jazz Pharmaceuticals Inc, Kiadis Pharma, Novartis, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: AbbVie Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlycoMimetics Inc, Novartis, Syros Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Pfizer Inc, Teva Oncology; Data and Safety Monitoring Board/Committee: AbbVie Inc, GlycoMimetics Inc, Takeda Oncology.
David Sallman, MD
Assistant Member
Malignant Hematology
Moffitt Cancer Center
Tampa, Florida
Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Aprea Therapeutics, Bristol-Myers Squibb Company, Intellia Therapeutics, Kite, A Gilead Company, Novartis, Shattuck Labs, Syndax Pharmaceuticals Inc; Consulting Agreements: Magenta Therapeutics, Takeda Oncology; Contracted Research: Aprea Therapeutics, Jazz Pharmaceuticals Inc; Speakers Bureau: Bristol-Myers Squibb Company, Incyte Corporation.
Eunice S Wang, MD
Chief, Leukemia Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Advisory Committee: AbbVie Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Kura Oncology, Novartis, PharmaEssentia, Stemline Therapeutics Inc; Consulting Agreements: Mana Therapeutics, Rafael Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: AbbVie Inc, Rafael Pharmaceuticals Inc; Speakers Bureau: Astellas, DAVA Oncology, Kura Oncology, Stemline Therapeutics Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AbbVie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc and Jazz Pharmaceuticals Inc.
Release date: November 2021
Expiration date: November 2022
(WIFI is recommended for best performance):